FDA-Drug2026-01-14Class IIPACKAGING DEFECT
Imprimis NJOF eye injection recalled for glass-like particles
What this means
Imprimis NJOF's dexamethasone-moxifloxacin-ketorolac eye injection contains glass-like particles that could contaminate the injection. This medication is used during eye surgery. The affected lots are 25APR001A and 25APR001B, expiring 04/03/2026.
- Do not use any syringes from lots 25APR001A or 25APR001B
- Contact your ophthalmologist or surgery center immediately if you have received this injection
- Report any eye problems or injuries to FDA MedWatch or your doctor
The agency's original wording
Hazard
Presence of particulate matter - Glass like particles.
Intended for
Adults
Illnesses reported
None reported
Sold states
U.S Nationwide
Affected count
596 boxes of 11,920 pre-filled syringes
Manufactured in
1705 Route 46 Ste 6B, Ledgewood, NJ, United States
Products
Dexamethasone Moxifloxacin Ketorolac, 1 mg/mL, 0.5 mg/mL, 0.4 mg/mL) Single-Use Intraocular Injection, Imprimis NJOF, LLC., 1705 Route 46 West, Unit 6B, Ledgewood, NJ 07852, NDC 71384-513-01.
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0250-2026Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.